Injection of E-selectin antagonist GMI-1271 mobilized AML blasts into the bloodstream, and deletion of E-selectin in primary recipients of AML cells increased LSC sensitivity to cytarabine treatment, assayed by limiting-dilution transplantation assays in wild-type recipients (Winkler et al., 2014). This evidence concerns the gene SELE and acute myeloid leukemia.